A detailed history of Legal & General Group PLC transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 17,443 shares of ITOS stock, worth $183,151. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,443
Previous 16,460 5.97%
Holding current value
$183,151
Previous $224,000 15.18%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$10.33 - $18.09 $10,154 - $17,782
983 Added 5.97%
17,443 $258,000
Q4 2023

Feb 15, 2024

SELL
$8.57 - $11.06 $411,479 - $531,034
-48,014 Reduced 74.47%
16,460 $180,000
Q3 2023

Nov 14, 2023

BUY
$10.95 - $14.6 $6,372 - $8,497
582 Added 0.91%
64,474 $705,000
Q2 2023

Aug 14, 2023

BUY
$12.93 - $18.05 $74,567 - $104,094
5,767 Added 9.92%
63,892 $845,000
Q1 2023

May 15, 2023

SELL
$13.02 - $22.62 $12,238 - $21,262
-940 Reduced 1.59%
58,125 $791,000
Q4 2022

Feb 14, 2023

BUY
$17.77 - $21.6 $26,850 - $32,637
1,511 Added 2.63%
59,065 $1.15 Million
Q3 2022

Nov 14, 2022

BUY
$18.6 - $27.25 $163,010 - $238,819
8,764 Added 17.96%
57,554 $1.1 Million
Q2 2022

Aug 22, 2022

BUY
$16.57 - $35.1 $55,012 - $116,532
3,320 Added 7.3%
48,790 $1.01 Million
Q1 2022

May 16, 2022

BUY
$31.92 - $47.45 $1.28 Million - $1.9 Million
40,137 Added 752.62%
45,470 $1.46 Million
Q4 2021

Feb 14, 2022

BUY
$26.23 - $47.86 $97,313 - $177,560
3,710 Added 228.59%
5,333 $249,000
Q2 2021

Aug 12, 2021

SELL
$17.9 - $36.1 $19,690 - $39,710
-1,100 Reduced 40.4%
1,623 $42,000
Q1 2021

May 17, 2021

BUY
$30.86 - $44.2 $47,215 - $67,626
1,530 Added 128.25%
2,723 $94,000
Q3 2020

Nov 13, 2020

BUY
$17.57 - $32.92 $20,961 - $39,273
1,193 New
1,193 $29,000

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $374M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.